Stock ACTI ACTIVE BIOTECH AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Active Biotech AB

Equities

ACTI

SE0001137985

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:01:59 2024-04-26 am EDT 		5-day change 1st Jan Change
0.567 SEK +6.38% Intraday chart for Active Biotech AB +2.53% +24.21%
Apr. 03 Active Biotech AB Announces Start of Enrollment to the Clinical Phase I Biodistribution Study with Laquinimod Eye Drops CI
Feb. 08 Active Biotech AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 326.8 274.5 275.5 254.8 205.1 205.1 -
Enterprise Value (EV) 1 326.8 274.5 223.1 254.8 128.9 205.1 205.1
P/E ratio -9.38 x -8.59 x - - - - -
Yield - - - - - - -
Capitalization / Revenue - 41 x - - - - 5.76 x
EV / Revenue - 41 x - - - - 5.76 x
EV / EBITDA - -8.85 x -4.6 x -4.52 x -2.88 x -4.77 x -13.3 x
EV / FCF - -8,524,750 x -4,829,919 x -4,650,020 x - - -
FCF Yield - -0% -0% -0% - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 145,236 145,236 217,972 264,887 361,739 361,739 -
Reference price 2 2.250 1.890 1.264 0.9620 0.5670 0.5670 0.5670
Announcement Date 2/6/20 2/11/21 3/25/22 2/9/23 2/8/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - 6.7 - - - - 35.6
EBITDA 1 - -31 -48.5 -56.4 -44.8 -43 -15.4
EBIT 1 - -32.3 -49.8 -57.9 -46.5 -43 -15.4
Operating Margin - -482.09% - - - - -43.26%
Earnings before Tax (EBT) 1 - -32.2 -49.8 - -45.8 -43 -15.4
Net income 1 -34.1 -32.2 -49.8 -58.4 -45.8 -43 -15.4
Net margin - -480.6% - - - - -43.26%
EPS -0.2400 -0.2200 - - - - -
Free Cash Flow - -32.2 -46.2 -54.8 - - -
FCF margin - -480.6% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 2/6/20 2/11/21 3/25/22 2/9/23 2/8/24 - -
1SEK in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - -
Net Cash position 1 - - 52.4 - 36.2 - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -32.2 -46.2 -54.8 - - -
ROE (net income / shareholders' equity) - - -145% - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 2/6/20 2/11/21 3/25/22 2/9/23 2/8/24 - -
1SEK in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ACTIVE BIOTECH AB Stock Active Biotech AB
+24.21% 18.71M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ACTI Stock
  4. Financials Active Biotech AB